GlassScriptPhysician profile
James Gurniak
NPI 1851420897
$18,793.14
in general payments reported to CMS, 2019-2025
41 companies · $2,444 in 2025
The $2,444 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,674 · 2020: $2,467 · 2021: $2,601 · 2022: $3,353 · 2023: $2,829 · 2024: $2,424 · 2025: $2,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,456 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,456.13 |
| Education | $241.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,016.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,829.59 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Lilly USA, LLC | $1,817.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,666.17 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,399.41 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $1,260.20 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,259.60 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $1,168.37 | 2019-2025 | Freestyle Libre |
| Pfizer INC. | $950.20 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $748.36 | 2022-2025 | |
| Amgen INC. | $619.50 | 2019-2024 | Prolia, Evenity |
| Horizon Therapeutics Plc | $493.65 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $449.59 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Astellas Pharma US INC | $436.24 | 2020-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $316.40 | 2019-2023 | Xarelto |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gurniak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.